About: Effect of ghrelin and anamorelin (ONO-7643), a selective ghrelin receptor agonist, on tumor growth in a lung cancer mouse xenograft model

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Effect of ghrelin and anamorelin (ONO-7643), a selective ghrelin receptor agonist, on tumor growth in a lung cancer mouse xenograft model Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Effect of ghrelin and anamorelin (ONO-7643), a selective ghrelin receptor agonist, on tumor growth in a lung cancer mouse xenograft model
Creator	Cheatham, L Kuroda, K Manning, E Northrup, R Pietra, C Routt Barnes, S Wiley, T
Source	PMC
abstract	PURPOSE: Anamorelin (ONO-7643) is an orally active ghrelin receptor agonist in development for non-small cell lung cancer (NSCLC)-related anorexia/cachexia. It displays both orexigenic and anabolic properties via ghrelin mimetic activity and transient increases in growth hormone (GH). However, increasing GH and insulin-like growth factor-1 in cancer patients raises concerns of potentially stimulating tumor growth. Therefore, we investigated the effect of ghrelin and anamorelin on tumor growth in a murine NSCLC xenograft model. METHODS: Female nude mice (15–21/group) with established A549 tumors were administered ghrelin (2 mg/kg i.p.), anamorelin (3, 10, or 30 mg/kg p.o.), or vehicle controls daily for 28 days. Tumor growth, food consumption, and body weight were monitored. Murine growth hormone (mGH) and murine insulin-like growth factor-1 (mIGF-1) were measured in plasma. RESULTS: Tumor growth progressed throughout the study, with no significant differences between treatment groups. Daily food consumption was also relatively unchanged, while the percentage of mean body weight gain at the end of treatment was significantly increased in animals administered 10 and 30 mg/kg compared with controls (p < 0.01). Peak mGH levels were significantly higher in ghrelin- and anamorelin-treated animals than in controls, while peak mIGF-1 levels were slightly elevated but not statistically significant. All regimens were well tolerated. CONCLUSIONS: These findings demonstrate that neither anamorelin nor ghrelin promoted tumor growth in this model, despite increased levels of mGH and a trend of increased mIGF-1. Together with anamorelin’s ability to increase body weight, these results support the clinical development of ghrelin receptor agonist treatments for managing NSCLC-related anorexia/cachexia.
has issue date	2013-04-12(xsd:dateTime)
bibo:doi	10.1007/s00520-013-1800-0
bibo:pmid	23579947
has license	no-cc
sha1sum (hex)	ff5323bf049107b9426ef22b59fee3aeae84c346
schema:url	https://doi.org/10.1007/s00520-013-1800-0
resource representing a document's title	Effect of ghrelin and anamorelin (ONO-7643), a selective ghrelin receptor agonist, on tumor growth in a lung cancer mouse xenograft model
has PubMed Central identifier	PMC3728440
has PubMed identifier	23579947
schema:publication	Support Care Cancer
resource representing a document's body	covid:ff5323bf049107b9426ef22b59fee3aeae84c346#body_text
is schema:about of	named entity 'mGH' named entity 'treatment groups' named entity 'plasma' named entity 'raises' named entity 'cancer' named entity 'TREATMENT' named entity 'TUMORS' named entity 'STUDY' named entity 'ADMINISTERED' named entity 'anabolic' named entity 'insulin-like growth factor' named entity 'higher' named entity 'agonist' named entity 'body weight' named entity 'measured' named entity 'NSCLC' named entity 'stimulating' named entity 'cachexia' named entity 'Therefore' named entity 'clinical development' named entity 'NSCLC' named entity 'gain' named entity 'group' named entity 'managing' named entity 'ghrelin' named entity 'insulin-like growth factor-1' named entity 'ghrelin receptor' named entity 'treatment groups' named entity 'agonist' named entity 'non-small cell lung cancer' named entity 'xenograft model' named entity 'Tumor growth' named entity 'anorexia' named entity 'Murine' named entity 'anamorelin' named entity 'body weight' named entity 'statistically significant' named entity 'anamorelin' named entity 'NSCLC' named entity 'agonist' named entity 'Anamorelin' named entity 'ONO-7643' named entity 'ghrelin receptor' named entity 'lung cancer' named entity 'However' named entity 'levels' named entity 'ghrelin' named entity '1, 2' named entity 'anamorelin' named entity 'cachectic' named entity 'short half-life' named entity 'secretion' named entity 'nude mice' named entity 'immunocompetent' named entity 'free base' named entity 'ghrelin' named entity 'isoflurane' named entity 'Tumor growth' named entity 'ghrelin' named entity 'NSCLC' named entity 'receptor' named entity 'Food consumption' named entity 'Matrigel' named entity 'peptide' named entity 'IGF-1' named entity 'tumor' named entity 'TGI' named entity '1.04' named entity 'tumor growth' named entity 'peak plasma levels' named entity 'anamorelin' named entity '5-FU' named entity 'log phase' named entity 'receptor' named entity 'streptomycin sulfate'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software